The Valley Desk

NCT06809140 · Interventional trial

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Overall registry status Recruiting

Phase 2

Conditions Muscle Invasive Bladder Urothelial Carcinoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov